Gossamer Bio, Inc. (GOSS) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 13, 2026, reports the financial results for Gossamer Bio, Inc. for the quarter ended June 30, 2026. The filing incorporates a press release (Exhibit 99.1) containing the detailed results.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. The document serves primarily as a notification that the press release has been issued.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q2 2026 financial figures.
- Verify cash runway and burn rate details in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the company provided updated full-year 2026 guidance in the attached exhibit.